Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 7/20 | 0.36 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060182 | 0.88 | DHFR (0.35) | PTPN1SLC6A4CA2CA1CA12 | |
| SCHEMBL13140899 | 0.87 | PDE4B (0.41) | PTPN1DHFRPDE4BHSD11B1MEN1 | |
| SCHEMBL13311130 | 0.83 | ACHE (0.49) | PTPN1CA2CA1CA12CA9 | |
| SCHEMBL12831493 | 0.82 | PTPN1 (0.39) | PTPN1CA2CA1CA12CA9 | |
| SCHEMBL7802721 | 0.81 | PTPN1 (0.37) | PTPN1CA2CA1DHFRPDE4B | |
| SCHEMBL1755976 | 0.80 | HSD11B1 (0.41) | PTPN1DHFRPDE4BHSD11B1MEN1 | |
| SCHEMBL2780758 | 0.79 | L3MBTL1 (0.42) | PTPN1 | |
| SCHEMBL5166212 | 0.79 | PTPN1 (0.38) | PTPN1DHFRPDE4BHSD11B1MEN1 | |
| SCHEMBL2497725 | 0.78 | KMT2A (0.49) | PTPN1CA2CA1CA12CA9 | |
| SCHEMBL12191799 | 0.78 | KMT2A (0.49) | PTPN1CA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| EP-1765792-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF STEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | Sterix Limited (GB) | 2007-03-28 | — | — | EP | disclosed |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STERIX LTD. | 2006-10-26 | — | — | US | disclosed |
| WO-2005115996-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF SEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | STERIX LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STS, SULT1E1, CYP19A1 | PTPN1 2952/4885SLC6A4 682/4885CA2 1885/4885 |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STS, SULT1E1, CYP19A1 | PTPN1 2686/4885SLC6A4 1405/4885CA2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.